Despite optimal initial emergency department (ED) therapy, 50% of children with severe acute asthma have ongoing moderate-severe respiratory distress. Guidelines recommend intravenous magnesium (IVMg) for them, yet evidence for IVMg efficacy is scant and disparate. While early small Randomized Controlled Trials (RCTs) suggested hospitalization benefit, recent large observational studies found no association between IVMg and improved outcomes. IVMg therapy is resource-intensive, can cause hypotension and demands close monitoring. Previous RCTs only assessed early Mg effect at 1-2 hours, overlooked the peak effect of key co-interventions such as corticosteroids and did not use validated scores. IVMg use is variable and often delayed until ≥4 hours after ED therapy is started and after the hospitalization decision has been made. Thus, in observational studies children given IVMg are 6-10 times more likely to be hospitalized; these studies have major confounding and the true IVMg treatment effect is thus unknown. To conclusively determine if IVMg alters the exacerbation course, it must be given early, and the primary outcome measure should be the severity of respiratory distress measured at the peak effect of key co-interventions to focus on a clinically meaningful and objective effect. The Pediatric Respiratory Assessment Measure (PRAM)-a valid, discriminative, reproducible and responsive-to-change instrument-is thus the ideal primary outcome measure. Hospitalization outcome has major confounding by indication and MD perceptions.
Primary Aim: In children with acute asthma remaining in moderate-severe distress after 1 hour of initial ED therapy, is early IVMg therapy associated with a significantly greater improvement in respiratory distress, measured by PRAM, at 3 hours after starting the intervention, compared to placebo? Hypothesis: IVMg will yield significantly greater PRAM improvement of ≥1.0 point than placebo.
Expected Outcomes: This trial will clarify if there is an incremental benefit of IVMg in decreasing respiratory distress in pediatric refractory acute asthma. A positive result will establish a proven standard of care for this indication, with a need for Knowledge Translation (KT) to implement routine early IVMg therapy. A negative result will lead to de-implementation of IVMg which may also lead to cost savings.

开始日期2025-09-01

申办/合作机构

The Hospital for Sick Children

[+5]

NCT06979141

/ Recruiting临床3期IIT

Comparative Study Between Efficacy of Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression During General Anesthetic Emergence

The aim of this prospective randomized controlled double-blinded study is to compare the efficacy of dexmedetomidine, MgSO4 and lidocaine for cough suppression during general anesthetic emergence as regard number and severity.

开始日期2025-06-02

申办/合作机构

Al-Azhar University

100 项与硫酸镁相关的临床结果

登录后查看更多信息

100 项与硫酸镁相关的转化医学

登录后查看更多信息

100 项与硫酸镁相关的专利（医药）

登录后查看更多信息

36,100

项与硫酸镁相关的文献（医药）

2025-12-31·Journal of Maternal-Fetal & Neonatal Medicine

Evaluation of fetal outcomes in dichorionic diamniotic twins with hypertensive disorders during pregnancy by the fetal middle cerebral artery and umbilical artery doppler

Article

作者: Lin, Xin ; Xu, Hai-hua ; Liu, Ling-ling

BACKGROUND:

Hypertensive disorders of pregnancy (HDP) is associated with the poor prognosis of dichorionic diamniotic (DCDA) twins. The prediction value of middle cerebral artery (MCA) and umbilical artery (UA) Doppler indices requires exploration.

OBJECTIVE:

To investigate the significance of the fetal MCA and UA doppler indices in DCDA fetal outcomes and depict hemodynamic alterations.

METHODS:

DCDA twin pregnancies were classified into the normotensive control group (n = 177) and the HDP group [n = 189, with 60 gestational hypertensions (GH) and 129 preeclampsia/eclampsia (PE/EC)]. Maternal and fetal outcomes were compared, the fetal MCA and UA doppler indices were analyzed, including pulsatility index (PI), resistance index (RI), the ratio of peak systolic blood flow velocity to end-diastolic blood flow velocity (S/D), and the mean velocities (Vm), and the cerebroplacental ratio (CPR) was computed for further study. The receiver operating characteristic curve was used to predict and evaluate small for gestational age (SGA) neonates in HDP twin pregnancies.

RESULTS:

Significant differences were shown between the HDP group and the normotensive control group in terms of maternal age, gestational weight gain, blood pressure, post 20-week urinary protein, the use of maternal medication utilization (magnesium sulfate, labetalol, dexamethasone), inter-twin growth discordance, and SGA (p < 0.05). In DCDA twins, the fetal MCA doppler indices (PI, RI and S/D) increased initially and then declined, UA indices (PI, RI and S/D) were declining, and both the Vm of MCA and UA were going up. In late DCDA twin pregnancies with GH, UA Doppler moderately predicted SGA neonates; in those with PE/EC, CPR did the same values (p < 0.05).

CONCLUSION:

In DCDA pregnancies complicated by hypertensive disorders, SGA twins exhibit distinct doppler deterioration patterns. Implementing customized monitoring strategies based on the fetal MCA and UA indices can effectively predict adverse conditions, enable timely interventions, and ensure fetal health.

2025-12-31·Environmental Pollutants and Bioavailability

Comprehensive toxicity assessment of selected pharmaceuticals (ciprofloxacin, amoxicillin, and levofloxacin) on freshwater microalgae Scenedesmus obliquus : effect of media composition

作者: Poddar, Bikram ; Mandal, Sanmitra ; Bhattacharya, Bikramjit ; Rex M, Camil ; Chandrsekaran, Natarajan ; Mukherjee, Amitava

Antibiotics are widely used in health care to treat various infections.Excessive use and poor waste management make antibiotics a serious threat to aquatic ecosystems.Most of the ecotoxicol. assessments on freshwater microalgae are evaluated in the defined culture medium, which lacks environmental relevance.Hence, this study aimed to evaluate the toxicity of amoxicillin, ciprofloxacin, and levofloxacin on the freshwater microalga Scenedesmus obliquus in both lake water medium (LWM) and Blue green-11 medium (BG-11 M).Results indicated that levofloxacin exhibited the highest toxicity, followed by amoxicillin and ciprofloxacin in both LWM and BG-11 M.Pearson correlation and cluster heat map analyses revealed that oxidative stress generation was directly linked to reduced photosynthetic activity and cell viability.These findings suggest toxicity assessments conducted in defined culture media may modulate the toxicity levels compared to environmentally relevant media, like lake water.

2025-12-31·HYPERTENSION IN PREGNANCY

Predictive value of 24-hour urine protein levels for adverse maternal and perinatal outcomes in hypertensive pregnancies

Article

作者: Coşkun, Ayhan ; Zeki Nessar, Ahmet ; Yıldız, Hamza ; Dal, Yusuf ; Çevikoğlu Kıllı, Mürşide ; Karagün, Şebnem ; Gamze Karaca, Sefanur

BACKGROUND:

Proteinuria is a widely used biomarker for risk stratification in hypertensive pregnancies, with potential predictive value for adverse maternal and perinatal outcomes. This study evaluated the predictive value of 24-hour urine protein levels for adverse maternal and perinatal outcomes in hypertensive pregnancies.

METHODS:

Higher proteinuria levels were significantly associated with increased rates of oligohydramnios (p = 0.001) and fetal growth restriction (FGR; p = 0.005), particularly in the > 2000 mg group (44.0% and 68.4%, respectively). Gestational age at delivery decreased with worsening proteinuria (p < 0.001), with the lowest mean age (32.84 ± 3.82 weeks) in the > 2000 mg group. Postpartum hospital stays were prolonged in chronic hypertension (p = 0.002) and severe proteinuria groups (p = 0.007). ROC analysis identified a 24-hour urine protein cutoff of 135 mg (AUC: 0.635, p = 0.001) for predicting fetal distress. The > 2000 mg group had universal magnesium sulfate use, earlier deliveries, and higher FGR rates. Chronic hypertension correlated with longer postpartum stays (p = 0.002) and higher postpartum renal disease (p = 0.040).

CONCLUSION:

These findings underscore proteinuria as a prognostic marker for adverse outcomes, supporting its role in risk stratification for hypertensive pregnancies. Future research should validate thresholds and explore targeted interventions.

104

项与硫酸镁相关的新闻（医药）

2025-05-25

·信狐药迅

轩竹生物乳腺癌新药吡罗西尼、海思科镇痛药HSK21542和北海康成罕见病用药维拉苷酶β获批上市| 新获批(5.19-5.25）

每周药品注册获批数据，分门别类呈现，一目了然。(5.19-5.25）新药上市申请药品名称企业注册分类受理号HSK21542注射液辽宁海思科制药有限公司1CXHS2300094吡罗西尼片轩竹生物科技股份有限公司1CXHS2300093吡罗西尼片轩竹生物科技股份有限公司1CXHS2300075盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHS2400069盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHS2400068盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHS2400067注射用维拉苷酶β北海康成(上海)生物科技有限公司1CXSS2400119贝莫苏拜单抗注射液正大天晴药业集团南京顺欣制药有限公司2.2CXSS2400082注射用卡瑞利珠单抗苏州盛迪亚生物医药有限公司2.2CXSS2300091新药临床申请药品名称企业注册分类受理号PRT-064040鼻喷雾剂四川普锐特药业有限公司1CXHL2500257PRT-064040鼻喷雾剂四川普锐特药业有限公司1CXHL2500256PRT-064040鼻喷雾剂四川普锐特药业有限公司1CXHL2500255HS-10510片江苏豪森药业集团有限公司1CXHL2500244HS-10510片江苏豪森药业集团有限公司1CXHL2500243SGB-3383注射液苏州圣因生物医药有限公司1CXHL2500238KEM2418缓释直服颗粒深圳珐玛易药品科技有限公司2.2CXHL2500252利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500250利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500249利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500248利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500247利奥西呱胃滞留缓释胶囊南京三迭纪医药科技有限公司2.2CXHL2500246TAP-1503 乳膏上海泽德曼医药科技有限公司2.4CXHL2500231BPR-102胶囊成都倍特益康恩生物医药科技有限公司1CXSL2500210BPR-102胶囊成都倍特益康恩生物医药科技有限公司1CXSL2500209FB1002重组人源化单克隆抗体注射液福贝生物医药科技(北京)有限公司1CXSL2500192皮炎诊断贴剂02贴浙江我武生物科技股份有限公司1CXSL2500195皮炎诊断贴剂02贴浙江我武生物科技股份有限公司1CXSL2500194皮炎诊断贴剂02贴浙江我武生物科技股份有限公司1CXSL2500193仿制药申请药品名称企业注册分类受理号维生素B6注射液上海禾丰制药有限公司3CYHS2501112氨溴特罗口服溶液湖北欣泽霏药业有限公司3CYHS2400652硫酸镁注射液河北一品制药股份有限公司3CYHS2400554美索巴莫注射液广州合和医药有限公司3CYHS2400448氯化钾颗粒福州基石医药科技有限公司3CYHS2400193氯化钾颗粒福州基石医药科技有限公司3CYHS2400192二羟丙茶碱注射液湖南柏齐鹤药物研发有限公司3CYHS2400173美索巴莫注射液海南普利制药股份有限公司3CYHS2400129醋酸葡萄糖维持液山东科伦药业有限公司3CYHS2400053醋酸葡萄糖维持液山东科伦药业有限公司3CYHS2400054重酒石酸间羟胺注射液武汉久安药业有限公司3CYHS2303676美索巴莫注射液北京沃邦医药科技有限公司3CYHS2303661注射用甲磺酸加贝酯石家庄四药有限公司3CYHS2303631复方电解质醋酸钠注射液山东科伦药业有限公司3CYHS2303623注射用比阿培南/氯化钠注射液湖南科伦制药有限公司3CYHS2303536异烟肼注射液广州绿十字制药股份有限公司3CYHS2303510二羟丙茶碱注射液华夏生生药业(北京)有限公司3CYHS2303378硫酸沙丁胺醇注射液山东华鲁制药有限公司3CYHS2303298二羟丙茶碱注射液武汉华尔生物科技有限公司3CYHS2303282硫酸镁注射液江西博泰药业有限公司3CYHS2303278氟马西尼注射液上海旭东海普药业有限公司3CYHS2303241氟马西尼注射液上海旭东海普药业有限公司3CYHS2303240注射用尼可地尔成都地奥九泓制药厂3CYHS2303209硫酸镁注射液焦作市民康药业有限公司3CYHS2303181甲硫酸新斯的明注射液云南先施药业有限公司3CYHS2303137甲硫酸新斯的明注射液云南先施药业有限公司3CYHS2303136生理氯化钠溶液华夏生生药业(北京)有限公司3CYHS2303121甲硫酸新斯的明注射液杭州民生药业股份有限公司3CYHS2303109甲硫酸新斯的明注射液杭州民生药业股份有限公司3CYHS2303108甲硫酸新斯的明注射液杭州民生药业股份有限公司3CYHS2303107重酒石酸去甲肾上腺素注射液中润药业有限公司3CYHS2303046重酒石酸去甲肾上腺素注射液中润药业有限公司3CYHS2303045地奈德软膏杭州领业医药科技有限公司3CYHS2303027复合磷酸氢钾注射液成都米子生物医药科技有限公司3CYHS2303010复合磷酸氢钾注射液成都欣捷高新技术开发股份有限公司3CYHS2303008酮咯酸氨丁三醇注射液广州一品红制药有限公司3CYHS2303001盐酸丙卡特罗颗粒江苏正大清江制药有限公司3CYHS2302905醋酸钠林格葡萄糖注射液成都赛诺联创生物科技有限公司3CYHS2302812复方电解质醋酸钠葡萄糖注射液仁合益康集团有限公司3CYHS2302807复方电解质醋酸钠葡萄糖注射液仁合益康集团有限公司3CYHS2302806醋酸钙口服溶液河北华晨药业集团有限公司3CYHS2302797盐酸去氧肾上腺素注射液安徽长江药业有限公司3CYHS2302659水合氯醛灌肠剂成都硕德药业有限公司3CYHS2302523利伐沙班颗粒南京海纳制药有限公司3CYHS2302484氯化钙注射液广州合和医药有限公司3CYHS2302480钠钾镁钙注射用浓溶液山东豪瑞恩制药有限公司3CYHS2302447盐酸利多卡因注射液云南药科院生物医药股份有限公司3CYHS2302400注射用阿莫西林钠广州艾奇西新药研究有限公司3CYHS2302386注射用阿莫西林钠广州艾奇西新药研究有限公司3CYHS2302385硫代硫酸钠注射液成都倍特药业股份有限公司3CYHS2302223富马酸酮替芬口服溶液海口天行健药物研究有限公司3CYHS2302211甲硫酸新斯的明注射液宝利化(南京)制药有限公司3CYHS2301868米诺地尔外用溶液浙江高跖医药科技股份有限公司3CYHS2301380卡络磺钠注射液海口天行健药物研究有限公司3CYHS2301262卡络磺钠注射液海口天行健药物研究有限公司3CYHS2301261米诺膦酸片安徽博诺美科生物医药有限公司3CYHS2301180利多卡因凝胶贴膏湖南九典制药股份有限公司3CYHS2300719卡络磺钠注射液四川汇宇海玥医药科技有限公司3CYHS2300666卡络磺钠注射液四川汇宇海玥医药科技有限公司3CYHS2300665依巴斯汀口服溶液南京海纳医药科技股份有限公司3CYHS2300635布洛氢可酮片宜昌人福药业有限责任公司3CYHS2201954国;CYHS2201954布洛氢可酮片宜昌人福药业有限责任公司3CYHS2201953国;CYHS2201953多潘立酮片温州海鹤药业有限公司4CYHS2402862甲泼尼龙片武汉九珑人福药业有限责任公司4CYHS2402356氧(液态)侨源气体(眉山)有限公司4CYHS2402288普拉洛芬滴眼液山东辰欣佛都药业股份有限公司4CYHS2401017沙格列汀二甲双胍缓释片江苏万高药业股份有限公司4CYHS2400993沙格列汀二甲双胍缓释片江苏万高药业股份有限公司4CYHS2400992盐酸伐地那非片江苏万高药业股份有限公司4CYHS2400984盐酸伐地那非片江苏万高药业股份有限公司4CYHS2400982吸入用乙酰半胱氨酸溶液海南皇隆制药股份有限公司4CYHS2400970孟鲁司特钠咀嚼片牡丹江恒远药业股份有限公司4CYHS2400855孟鲁司特钠咀嚼片牡丹江恒远药业股份有限公司4CYHS2400854妥布霉素滴眼液浙江赛默制药有限公司4CYHS2400761马来酸氟伏沙明片合肥英太制药有限公司4CYHS2400736马来酸氟伏沙明片合肥英太制药有限公司4CYHS2400735马来酸氟伏沙明片苏州第三制药厂有限责任公司4CYHS2400617马来酸氟伏沙明片苏州第三制药厂有限责任公司4CYHS2400616硫酸氨基葡萄糖胶囊江苏润邦药业有限公司4CYHS2400579马来酸氟伏沙明片江苏诺泰澳赛诺生物制药股份有限公司4CYHS2400595乙酰半胱氨酸泡腾片浙江赛默制药有限公司4CYHS2400520双氯芬酸钠缓释片锦州奥鸿药业有限责任公司4CYHS2400513双氯芬酸钠缓释片锦州奥鸿药业有限责任公司4CYHS2400512丙戊酸钠口服溶液山东达因海洋生物制药股份有限公司4CYHS2400465盐酸决奈达隆片石家庄四药有限公司4CYHS2400464盐酸奥洛他定滴眼液石家庄格瑞药业有限公司4CYHS2400399溴莫尼定噻吗洛尔滴眼液石家庄格瑞药业有限公司4CYHS2400335盐酸伐地那非片广州绿十字制药股份有限公司4CYHS2400334地夸磷索钠滴眼液深圳市华生元基因工程发展有限公司4CYHS2400318间苯三酚注射液常州四药制药有限公司4CYHS2400234吸入用丙酸倍氯米松混悬液河北创健药业有限公司4CYHS2400231盐酸伊立替康脂质体注射液无锡济煜山禾药业股份有限公司4CYHS2400207盐酸奥洛他定滴眼液乐信乐美(海南)生物科技有限公司4CYHS2400163硫酸氨基葡萄糖胶囊武汉维奥制药有限公司4CYHS2400157地夸磷索钠滴眼液郑州卓峰制药有限公司4CYHS2400151奥美沙坦酯氨氯地平片珠海润都制药股份有限公司4CYHS2400029曲伏噻吗滴眼液山东辰欣佛都药业股份有限公司4CYHS2400034注射用头孢唑肟钠安徽省先锋制药有限公司4CYHS2303664注射用头孢唑肟钠安徽省先锋制药有限公司4CYHS2303663利托那韦片福建广生中霖生物科技有限公司4CYHS2303569左氧氟沙星滴眼液山东辰欣佛都药业股份有限公司4CYHS2303542奥美沙坦酯氨氯地平片宁波大红鹰药业股份有限公司4CYHS2303522注射用盐酸美法仑凯信远达医药(无锡)有限公司4CYHS2303513注射用头孢他啶/氯化钠注射液湖南科伦制药有限公司4CYHS2303472注射用氯诺昔康天津梅花生物医药科技有限公司4CYHS2303416布洛芬混悬滴剂山东新华制药股份有限公司4CYHS2303315布洛芬混悬滴剂山东新华制药股份有限公司4CYHS2303314二甲双胍恩格列净片(I)浙江易泽达医药科技有限公司4CYHS2303310罗沙司他胶囊重庆圣华曦药业股份有限公司4CYHS2303284罗沙司他胶囊重庆圣华曦药业股份有限公司4CYHS2303283苯磺酸左氨氯地平片山东鲁抗医药股份有限公司4CYHS2303187苯磺酸左氨氯地平片山东鲁抗医药股份有限公司4CYHS2303186盐酸贝尼地平片上海安必生制药技术有限公司4CYHS2303185利奈唑胺葡萄糖注射液北京吉洛华制药有限公司4CYHS2303183枸橼酸托法替布片国药集团容生制药有限公司4CYHS2303134盐酸乌拉地尔注射液江苏迪赛诺制药有限公司4CYHS2303114达格列净二甲双胍缓释片(IV)浙江华海药业股份有限公司4CYHS2303039达格列净二甲双胍缓释片(III)浙江华海药业股份有限公司4CYHS2303038达格列净二甲双胍缓释片(I)浙江华海药业股份有限公司4CYHS2303037达格列净二甲双胍缓释片(I)浙江华海药业股份有限公司4CYHS2303036黄体酮软胶囊浙江仙琚制药股份有限公司4CYHS2302889黄体酮软胶囊浙江仙琚制药股份有限公司4CYHS2302888碘普罗胺注射液博瑞制药(苏州)有限公司4CYHS2302630碘普罗胺注射液博瑞制药(苏州)有限公司4CYHS2302629注射用硼替佐米瑞阳制药股份有限公司4CYHS2302231莫匹罗星软膏海南紫程众投生物科技有限公司4CYHS2302106注射用头孢哌酮钠舒巴坦钠浙江惠迪森药业有限公司4CYHS2302052盐酸度洛西汀肠溶胶囊北京四环制药有限公司4CYHS2300590盐酸度洛西汀肠溶胶囊北京四环制药有限公司4CYHS2300589盐酸度洛西汀肠溶胶囊北京四环制药有限公司4CYHS2300588多种油脂肪乳注射液(C6-24)四川科伦药业股份有限公司4CYHL2500048多种油脂肪乳注射液(C6-24)四川科伦药业股份有限公司4CYHL2500047进口申请药品名称企业注册分类受理号盐酸阿思尼布片Novartis Pharma Schweiz AG2.4JXHS2400043琥珀酸瑞波西利片Novartis Pharma Schweiz AG2.4JXHS2300126乙酰半胱氨酸注射液Zambon Switzerland Ltd.5.1JXHS2200025国;JXHS2200025注射用替奈普酶Boehringer Ingelheim International GmbH2.2JXSS2400001注射用坦昔妥单抗Incyte Biosciences Distribution B.V.3.1JXSS2400050MK-7240注射液Merck Sharp & Dohme LLC1JXSL2500037中药相关申请药品名称企业注册分类受理号开心散上海和黄药业有限公司3.1CXZS2400024注：橙色字体部分结论为不批准或收到通知件；

上市批准申请上市

2025-05-23

·顿斯制药

创新驱动，共筑医药健康新未来——顿斯药业亮相第90届全国药交会

共襄盛会五月羊城，繁花似锦。2025年5月21日-23日，第90届全国药品交易会在广州中国进出口商品交易会展中心隆重举行。本届药交会吸引了来自全国各地的2000余家知名药企及500余名行业专家齐聚一堂，共探医药行业发展趋势与市场机遇。顿斯药业集团携多款核心产品重磅参展，展台前咨询洽谈的新老客户络绎不绝，并与多地客户达成初步合作意向。展台盛况：专业赋能，精准对接需求顿斯药业展位以“医药赋能健康，品质守护生命”为设计理念，通过数字化交互、产品动态演示及现场答疑等方式，全面展示企业的核心产品矩阵。其中，立美舒®硫酸镁散剂为独家医保甲类品种，具备口服导泻/利胆及外用消肿三重药理作用，在消化、肛肠、骨科等领域应用广泛；乳酸依沙吖啶溶液是685基药目录及医保乙类产品，作为临床创面管理的一线用药，适用于皮肤科、肛肠科、烧伤科、妇产科等多科室；甲硝唑胶浆含漱液为全国独家、口腔推注用药新选择；复方愈创木酚磺酸钾口服溶液是独家无糖配方适应糖尿病/控糖人群，拓宽适用患者池。愈创木酚磺酸钾（祛痰）+维生素C（免疫支持），符合呼吸道疾病综合管理趋势；复方苯海拉明麻黄碱糖浆为全国独家、儿童剂量精确，解决家长给药焦虑；注射用头孢拉定是化合物专利，精氨酸配方提升稳定性或降低刺激性，延长产品生命周期。为提升观展体验，顿斯药业特别设置产品体验区与专家咨询区，参会者可现场体验不同产品试用效果，顿斯药业营销团队与前来咨询的客户面对面交流，讲解产品临床优势，为客户深度答疑解惑。顿斯药业集团始终坚持“解决临床问题，让患者获益”的理念，通过创新研发与经典产品升级双轮驱动，为市场提供差异化解决方案，顿斯药业与合作伙伴共拓市场新机遇，助力健康中国战略。一位与顿斯药业合作多年的代理商表示：“顿斯的产品不仅通过联盟集采验证了价格优势，其稳定的供应能力和严格的质量控制体系更让我们放心深化合作。”合作突破：创新模式助力共赢在三天的密集洽谈中，顿斯药业与多地客户达成合作意向，覆盖药品销售、市场拓展等。顿斯药业集团黎丽莎总裁带领集团营销核心团队与多家企业达成深度合作意向，黎丽莎总裁表示，顿斯药业将继续以“专家建设为中心，以循证医学为抓手”，全面构建学术营销体系，面向市场精准招商、精细化管理&服务及专业化学术支持，推动存量批文转化与重磅单品孵化，与合作伙伴共享行业红利，同时优化产品组合，为合作伙伴提供差异化竞争力，让伙伴们安心经营，长远发展。行业前瞻：以质取胜，锚定高质量发展多年来，顿斯药业始终坚持“以生命守护生命”的医药行业本质，用专业和服务赢得市场。顿斯药业旗下的陕西顿斯、河北武罗、西藏邦臣三大生产基地已全面运营，这为顿斯药业未来的发展奠定了坚实的基础。顿斯药业将以本次展会为契机，进一步深化“专业化、精细化、学术化”的市场战略，加速布局口服与外用药特色、独家品种赛道，深耕医药领域，专注特色化、差异化产品研发与生产，致力于成为“临床刚需用药领军企业”，持续以创新为引擎，与行业伙伴聚势共赢。海阔凭鱼跃，天高任鸟飞。本次药交会不仅为顿斯药业提供了展示实力的舞台，更成为链接上下游、共谋未来的重要契机。顿斯药业正以品质为基、创新为翼，携手合作伙伴擘画医药健康产业的新蓝图。企业简介顿斯药业集团是一家集药品研发、生产和流通销售于一体的医药集团企业。集团旗下有陕西顿斯制药有限公司、河北武罗药业有限公司、西安汤臣制药有限公司等药品生产企业。顿斯药业积极响应国家的产业发展规划，秉承科技引领、绿色发展、创新发展的基本理念，以提升原有产品质量水平，开发创新产品为根本任务，提升企业发展质量和产品市场竞争力，以实际行动为推进健康中国，全面建成小康社会，作出医药企业一流的贡献。继续加大研发投入，推出更具创新性的产品，以满足市场需求。免责声明1.“顿斯制药”部分文章信来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。 2.“顿斯制药”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。 3.“顿斯制药”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“顿斯制药”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。4.“顿斯制药”部分图片来自网络。END029-84210968陕西省西安市莲湖区唐延路北段太和时代广场A座

医药出海

2025-05-20

·EINPresswire

Magnesium Injection Provides Value-based Therapy For Arthritis; Olumuyiwa Bamgbade, Salem Pain Clinic, Canada

Magnesium Injection Therapy Is Effective And Safe For Severe Arthritis Pain; Dr. Olumuyiwa Bamgbade, Salem Pain Clinic, BC, Canada Magnesium injection represents a value-based, steroid-free therapy for severe arthritis pain” — Dr. Olumuyiwa Bamgbade SURREY, BC, CANADA, May 20, 2025 / EINPresswire.com / -- Arthritis pain can be debilitating and may require injection therapy. Steroid injections, while common, come with risks, including immunosuppression and systemic effects. The need for safer and economically sustainable treatments has never been more urgent. A new study published in the SVOA Medical Research journal shows that injecting magnesium around the joints can effectively reduce arthritis pain and is a safe, affordable, and value-based option compared to steroid injections. It highlights that steroid-free injection therapy is especially beneficial for patients with sickle cell disease (SCD) arthropathy. Led by Dr. Olumuyiwa Bamgbade and the Salem Anaesthesia Pain Clinic , the study evaluated 20 adult males who suffered from severe hip or knee arthropathy. Participants received ultrasound-guided periarticular injections of either magnesium sulfate (1000 mg) or dexamethasone (10 mg) at four-month intervals. Magnesium and dexamethasone equally led to approximately 75% pain reduction, improved sleep quality (50%), and enhanced mobility (75%) based on validated scales. No complications were observed from magnesium injections. In contrast, two patients experienced transient complications from Dexamethasone injections. Magnesium injections cost $1 per dose of 1000mg, while dexamethasone injections cost $2 per dose of 10mg. This study has implications for value-based healthcare. Magnesium injection therapy aligns with the principles of value-based care. It provides comparable clinical outcomes to standard steroid therapy. It mitigates unnecessary healthcare costs associated with steroid-related adverse events. Magnesium injections minimize complication risks, especially in vulnerable populations. It supports long-term functional independence and quality of life for arthritis patients. Indeed, periarticular magnesium injection represents a promising, steroid-free approach to managing arthritis pain in high-risk patients. It exemplifies the shift toward value-based, patient-centered care in musculoskeletal medicine, offering cost-effective relief without compromising efficacy. Dr. Bamgbade is a healthcare leader with an interest in value-based healthcare delivery. He is a specialist physician trained in Nigeria, Britain, the USA, and South Korea. He is an adjunct professor at institutions in Africa, Europe, and North America. He has collaborated with researchers in Nigeria, Australia, Iran, Mozambique, Rwanda, the USA, Kenya, Armenia, South Africa, Britain, Tanzania, Namibia, Zambia, Botswana, China, Ethiopia, Jamaica, and Canada. He has published 45 scientific papers in PubMed-indexed journals. He is the director of Salem Pain Clinic, a specialist and research clinic in Surrey, BC, Canada. Dr. Bamgbade and Salem Pain Clinic focus on researching and managing pain, health equity, injury rehabilitation, neuropathy, insomnia, societal safety, substance misuse, medical sociology, public health, medicolegal science, and perioperative care. References Bamgbade OA, Allen AM, Bamgbade DO, Tase NE, Donyagardrad H, Bada BE, Motshana T, Chorna O, Chansa M, Gitonga GG, Khanyile TM, Manuel B, Remwa R, Irakoze A. Periarticular Magnesium Injection Therapy Provides Pain Relief and Enables Steroid Avoidance in Sickle Cell Arthropathy Patients. SVOA Medical Research 2025, 3:3, 84-91. EIN Presswire. Healthcare Leadership Failures Require Metrics and Meritocracy Reforms. Fox 21 News 2025 (April 21). EIN Presswire. The Need to Teach Resourcefulness Initiatives in Human Care Systems. WJHL News 2025 (January 14). Fernández-Salido M, Alhambra-Borrás T, Casanova G, Garcés-Ferrer J. Value-Based Healthcare Delivery: A Scoping Review. International Journal of Environmental Research and Public Health. 2024, 21(2):134. Olumuyiwa Bamgbade Salem Anaesthesia Pain Clinic +1 778-628-6600 salem.painclinic@gmail.com Visit us on social media: LinkedIn Other Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床结果

100 项与硫酸镁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	D11AX05 A06AD04 A12CC02	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
电解质不平衡	日本	Otsuka Pharmaceutical Factory, Inc.	2008-03-13
先兆子痫	美国	Hospira, Inc.	1994-06-24
低镁血症	澳大利亚	Pfizer Australia Pty Ltd.	1991-10-08
癫痫发作	澳大利亚	Pfizer Australia Pty Ltd.	1991-10-08
肾低镁血症2	美国	Fresenius Kabi USA LLC	1986-09-08

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部肿胀	临床1期	中国	石家庄鹏海制药股份有限公司	2023-12-29
局部肿胀	临床1期	中国	石家庄杏泽医药科技有限公司	2023-12-29
创伤和损伤	临床申请批准	中国	广东迈恒医药研发有限公司	2025-06-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2025	N/A	哮喘持续状态	226	Magnesium Sulfate	範觸鬱憲憲觸憲網醖築(齋襯衊選簾艱鑰憲鑰選) = 膚蓋簾餘窪製製醖齋膚鏇願糧糧範膚餘襯觸觸 (願鏇簾衊艱製觸憲構膚, 2.9 ~ 5.6) 更多	不佳	2025-05-16
				No Magnesium Sulfate	範觸鬱憲憲觸憲網醖築(齋襯衊選簾艱鑰憲鑰選) = 衊蓋願顧範餘繭齋淵廠鏇願糧糧範膚餘襯觸觸 (願鏇簾衊艱製觸憲構膚, 2.0 ~ 3.5) 更多
NCT06603766 (PPHN, CTgov)	临床2/3期	肺动脉高压	40	Inhalational magnesium sulfate (Nebulized Magnesium (NebMag) Group 1)	製廠鏇積夢齋構獵觸鏇(齋繭壓遞積糧遞鹽鬱製) = 願膚艱艱壓襯簾簾網壓蓋窪淵網製願艱夢繭鏇 (鹽範網鏇願積淵醖壓觸, 1.29) 更多	-	2025-02-05
				IV Magnesium Sulfate (Intravenous Magnesium (IVMag) Group 2)	製廠鏇積夢齋構獵觸鏇(齋繭壓遞積糧遞鹽鬱製) = 鏇鹹鏇鹽餘鏇構襯齋醖蓋窪淵網製願艱夢繭鏇 (鹽範網鏇願積淵醖壓觸, 1.18) 更多
NCT05166811 (IMPACT-ED, CTgov)	临床2期	哮喘	52	0.9% saline (Placebo)	鏇積繭鑰遞範鏇範積淵 = 蓋獵憲鹽鹽窪衊觸積選選願鏇選顧觸蓋艱糧鬱 (築鑰鬱淵鹹繭築網淵醖, 鹽壓醖餘鬱壓餘窪鹽願 ~ 願壓壓觸壓願糧醖鏇淵) 更多	-	2024-12-18
				Magnesium Sulfate, Heptahydrate (50 mg/kg)	鏇積繭鑰遞範鏇範積淵 = 衊壓醖鹹選積積齋簾積選願鏇選顧觸蓋艱糧鬱 (築鑰鬱淵鹹繭築網淵醖, 鹽範繭鑰鹽鬱廠範鑰繭 ~ 鑰衊齋壓選窪淵範淵餘) 更多
NCT05967442 (MAGraine, CTgov)	临床3期	急性偏头痛 \| 头痛	157	Magnesium sulfate (Magnesium)	構簾製艱築鑰醖獵積願(鏇鹽窪餘網網網糧蓋齋) = 憲鑰積製簾構壓壓醖糧憲壓膚鑰顧鹽夢積鹹衊 (襯糧顧餘餘鹽膚鏇製選, 選鏇觸夢鹽齋鬱觸構範 ~ 願鹹淵獵鹽簾構壓廠窪) 更多	-	2024-10-01
				Metoclopramide 10mg (Metoclopramide)	構簾製艱築鑰醖獵積願(鏇鹽窪餘網網網糧蓋齋) = 窪壓夢積顧鬱鏇淵鑰淵憲壓膚鑰顧鹽夢積鹹衊 (襯糧顧餘餘鹽膚鏇製選, 製鹽簾艱齋製蓋觸齋繭 ~ 艱廠範構艱觸壓觸築構) 更多
NCT04638881 (MgPOEM, CTgov)	临床2期	弥漫性食管痉挛	92	Magnesium sulfate (Magnesium Sulfate 50 mg/kg Bolus + 25 mg/kg/hr Infusion)	糧築簾構衊醖醖築壓積(淵鬱鑰遞衊觸鹹鑰窪襯) = 簾鏇繭夢鬱齋簾獵夢遞網鹽顧鹹範選選壓築膚 (衊壓壓窪糧鑰憲積廠獵, 餘願獵積醖襯築顧鑰壓 ~ 夢繭築獵簾遞積鏇繭積) 更多	-	2024-05-21
				Normal Saline (Normal Saline 0.9% 50 mg/kg Bolus + 25 mg/kg/hr Infusion)	糧築簾構衊醖醖築壓積(淵鬱鑰遞衊觸鹹鑰窪襯) = 窪觸製觸夢鏇餘顧遞獵網鹽顧鹹範選選壓築膚 (衊壓壓窪糧鑰憲積廠獵, 衊衊鹽膚鹹襯鬱構鹹壓 ~ 餘餘夢餘範鑰遞顧積獵) 更多
ESH2024	N/A	先兆子痫	182	Magnesium Sulfate 12 hours	築鹹淵艱遞遞壓壓觸鬱(構蓋窪築鹽鬱製窪鹽夢) = adverse effects were similar in both groups 窪觸廠積繭憲願衊積獵 (選鏇鏇窪糧醖鹽憲鏇醖 )	积极	2024-05-01
NCT00059332 (FAST-MAG, Pubmed \| Stroke) 人工标引	临床3期	脑出血 serum magnesium level	189	Magnesium sulfate	淵製艱觸築積夢鹹積鬱(憲衊鹽膚衊遞壓繭鹹襯) = 製艱繭壓鬱壓齋窪簾遞蓋獵廠淵願蓋選夢廠膚 (鏇糧製醖鹹鬱廠鹹製顧, 0.42 ~ 0.93) 更多	积极	2024-02-01
				Placebo	-
NCT02091401 \| NCT03661775 \| NCT02396030 \| NCT01846156 \| NCT02835339 \| NCT02317146 \| NCT03112551 \| NCT03549767 \| NCT03164304 \| NCT03318211 (Pubmed \| Cochrane Database Syst Rev)	N/A	子痫 \| 先兆子痫	-	Short magnesium sulphate maintenance regimen	觸顧蓋鹹淵鑰壓築製製(網範範繭觸範醖遞襯鑰) = Low-certainty evidence suggests an uncertain effect with either regimen on the risk of eclampsia 觸鹹襯蓋構淵衊繭蓋獵 (鹹繭製鹽襯廠構膚構網 ) 更多	-	2023-10-10
				Standard 24 hours magnesium sulphate maintenance regimen
ChiCTR2300070595 (Pubmed \| BMC Anesthesiol)	临床3期	躁动	70	Magnesium Sulfate	獵憲壓積範鏇觸鹽範憲(鏇築鏇構繭範簾網鹹憲): odds ratio = 0.26 (95% CI, 0.09 ~ 0.71), P-Value = 0.009 更多	积极	2023-09-26
				0.9% saline
NCT04539249 (OFAAPPCS, CTgov)	N/A	镇痛 \| 术后疼痛	324	Magnesium sulphate (Magnesium Sulphate)	廠鬱鬱壓齋繭範構蓋築(鹽繭鬱衊餘壓膚鹽觸廠) = 襯積餘淵夢淵衊簾齋觸製製製壓積餘糧繭網構 (鹹觸構壓築簾願蓋鬱製, 1.18) 更多	-	2023-07-20
				Pentazocine (Pentazocine)	廠鬱鬱壓齋繭範構蓋築(鹽繭鬱衊餘壓膚鹽觸廠) = 構淵製廠範顧顧憲夢繭製製製壓積餘糧繭網構 (鹹觸構壓築簾願蓋鬱製, 1.45) 更多